Home >> HealthCenter >> ClinicalTrial

"MOTIV" Study. Effect of Antidepressive Treatment by Escitalopram in Patients Undergoing Coronary Artery Bypass Grafting

This study is currently recruiting participants.
Verified by Hopital Jean Minjoz July 2007

Sponsors and Collaborators:

Hopital Jean Minjoz

H. Lundbeck A/S

Information provided by:

Hopital Jean Minjoz

ClinicalTrials.gov Identifier:

NCT00243477

 

Purpose

The purpose of this study is to determine the effect of an antidepressive medication (Escitalopram), started preoperatively and given during 6 months, on 6-month and 1 year post-operative morbidity and mortality after coronary artery bypass grafting

Condition

Intervention

Phase

Coronary Artery Disease
Surgery

 Drug: Escitalopram

Phase IV

MedlinePlus related topics:  Coronary Artery Disease
Genetics Home Reference related topics:  Coronary Artery Disease

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Number of arms in study:  2

Official Title: "MOTIV" Study. Effect of Antidepressive Treatment by Escitalopram Started Preoperatively in Patients Undergoing Coronary Artery Bypass Grafting

Primary Outcome Measures: 

  • All cause mortality [Time Frame: 6 months and 1 year]
  • All cause morbidity [Time Frame: 6 months and 1 year]


Secondary Outcome Measures: 

  • Quality of life [Time Frame: preoperatively and 1,3,6, and 12 months post-operatively]
  • Beck depression index [Time Frame: preoperatively, and 1,3,6, and 12 months post-operatively.]

Further study details as provided by Hopital Jean Minjoz:


Total Enrollment:  400

Study start: January 2006;  Expected completion: January 2009

Depression is known to have an adverse effect on post-operative mortality and morbidity after coronary artery bypass grafting. Cardiac surgery is known to cause transient depression in patients. The purpose of this double-blind, randomized study is to determine the effect of an antidepressive medication (Escitalopram), started preoperatively and given during 6 months, on 6-month and 1 year post-operative morbidity and mortality after coronary artery bypass grafting. Treatment is given from 21 to 15 days pre-operatively until the 6th post-operative month. Morbidity as defined by the STS database as well as mortality is checked during 1 year.

 

1234
Next

Home   |   About Us   |   Contact Us   |   Privacy   |   Terms Of Use   |   Advertise With Us   |   Sitemap
Copyright © 2019 Responsive Health
This site is intended to provide you with health information from publicly available sources, supporting vendors and partnered sources. While We make every effort to ensure that the information on this site is accurate, We make absolutely no assumption, inference, or declaration stating the information provided should be use as a source influencing any decisions on medical, diagnosis or treatment, or advice about what providers to use. The Site is an informational resource used for educational purposes only and cannot be used as a source used to make changes to medical treatment or lifestyle decisions without first consulting with your physician.